Hep C - euro adhoc: Intercell AG / Financial Figures

euro adhoc: Intercell AG / Financial Figures
VWDNews - Vienna (Austria), March 6, 2006 - Vaccine company Intercell AG (VSE: ICLL) today announced its preliminary 2005 full year results. Intercell?s aggregate annual revenues increased from EUR 4.6 million in 2004 to EUR 8.5 million in 2005, or by 84.9

NEIGHBORHOODS CALENDAR
Californian - More than 150 performers will celebrate St. Patrick's Day by performing Irish and Celtic music at Hartnell College's "Irish Extravaganza" banquet March 17. The event runs from 6:30 to 10 p.m. in the Steinbeck Hall of the College Center, and features

NDRI Researchers Evaluate Prison Hepatitis Program
Medical News Today - In an article published in the Journal of Correctional Health Care, researchers from the National Development and Research Institutes, Inc. (NDRI) reported on an evaluation of an intervention program within a prison system addressing Hepatitis C

Human Genome tumbles on mixed drug data
Investors Business Daily - BOSTON (MarketWatch) -- Human Genome Sciences shares tumbled Tuesday following the release of mixed Phase II clinical data for its biologic drug candidate to treat hepatitis C, Albuferon. Shares of Human Genome sank 20% to close at $10.89. In a

Human Genome Sciences
Forbes - Piper Jaffray maintained an "outperform" rating on Human Genome Sciences and advised investors to buy on recent weakness in the stock. Shares of Human Genome Sciences (nasdaq: HGSI - news - people ) plunged 20% last Tuesday after the biotech firm